Oncology Today with Dr Neil Love

View Top 200 Chart

Back to Rankings Page

Health & Fitness
**Oncology Today with Dr Neil Love**

Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.

Latest Episodes:

Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 6 Oct 28, 2026

Show notes

Featuring perspectives from Dr Lindsey Roeker, including the following topics:

Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab and experiences an excellent response (0:00)
Case: A man in his late 70s with small lymphocytic lymphoma (SLL) and cardiovascular comorbidities requiring verapamil and anticoagulation receives acalabrutinib/venetoclax; Case: A man in his early 80s with SLL receives zanubrutinib/sonrotoclax as part of the CELESTIAL-TNCLL trial (14:46)
Case: A man in his late 70s with progressive CLL worsening after a skiing injury receives acalabrutinib/venetoclax as part of the MAJIC trial (22:37)

CME information and select publications

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 5 Oct 28, 2026

Show notes

Featuring perspectives from Dr Lindsey Roeker, including the following topics:

Consensus Approach to optimizing front-line treatment (0:00)
Emerging role of sonrotoclax (8:39)
Bruton tyrosine kinase inhibitor monotherapy for older patients; discontinuation (14:48)
Evolving role of minimal residual disease assessment (19:16)

CME information and select publications

Ovarian Cancer — Microlearning Activity 4: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer Oct 27, 2026

Show notes

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:

Case: A woman in her early 70s with endometrioid carcinoma of the ovary and a large solitary brain metastasis after primary debulking surgery and adjuvant carboplatin/paclitaxel — Professor Jonathan A Ledermann (0:00)

CME information and select publications

Ovarian Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer Oct 26, 2026

Show notes

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:

Case: A woman in her late 60s with a germline BRCA2 mutation and heavily pretreated ovarian cancer receives weekly nab paclitaxel and relacorilant — Angeles Alvarez Secord, MD, MHSc (0:00)

CME information and select publications

Prostate Cancer — An Interview with Prof Karim Fizazi Oct 23, 2026

Show notes

Featuring an interview with Prof Karim Fizazi, including the following topics:

Perspectives on the PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy for high-risk localized prostate cancer (0:00)
Mechanism of action of opevesostat and potential role in castration-resistant prostate cancer with androgen receptor mutations (15:37)
Perspectives on alpha- and beta-emitting radiopharmaceuticals in the treatment of prostate cancer (22:47)
Novel antibody-drug conjugates and proteolysis-targeting chimeras (30:43)
Treatment approaches for metastatic hormone-sensitive prostate cancer — de novo symptomatic presentation versus PSMA-only metastatic recurrence after local therapy (34:51)
Role of intermittent therapy in the treatment of prostate cancer (38:48)
Treatment intensification approaches in prostate cancer (41:38)
Case: A man in his late 60s with de novo PSMA PET-positive metastatic castration-sensitive prostate cancer (45:25)

CME information and select publications

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 4 Oct 23, 2026

Show notes

Featuring perspectives from Prof Susana Banerjee, including the following topics:

Case: A woman in her mid 50s with multiregimen-recurrent low-grade serous ovarian cancer and a KRAS G12V mutation who receives avutometinib/defactinib with response, asymptomatic creatine phosphokinase elevation and mild facial rash — Dr Stover (0:00)
Case: A woman in her early 30s with recurrent metastatic low-grade serous ovarian cancer, originally offered hospice due to poor condition, who receives avutometinib/defactinib with an excellent response — Dr Hussein (7:58)
Case: A woman in her late 30s with multiregimen-recurrent folate receptor alpha-positive low-grade serous ovarian cancer (HER2 IHC 2+) who receives mirvetuximab soravtansine — Dr Cobb (18:21)

CME information and select publications

Low-Grade Serous Ovarian Cancer — 5-Minute Journal Club: Microlearning Activity 3 Oct 22, 2026

Show notes

Featuring perspectives from Prof Susana Banerjee, including the following topics:

Overview of the biology and treatment of low-grade serous ovarian cancer (0:00)
Mechanism of action of avutometinib/defactinib (10:16)
RAMP 201 Trial: Avutometinib/defactinib in recurrent low-grade serous ovarian cancer (14:32)
Ongoing clinical trials in low-grade serous ovarian cancer (27:57)

CME information and select publications

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome Oct 21, 2026

Show notes

Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:

Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)
Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58)
Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40)
Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50)
Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39)
Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50)
Case: A woman in her early 70s with FL receives epcoritamab (1:26:38)
Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28)
Case: A woman in her late 40s with FL receives epcoritamab (1:38:33)
Case: A man in his early 70s with mantle cell lymphoma receives mosunetuzumab (1:46:26)

CME information and select publications

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies Oct 17, 2026

Show notes

Featuring a slide presentation from Dr Julia Rotow, including the following topics:

Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00)
Key findings from the Phase III HARMONi-6 study; ongoing Phase III HARMONi-3 study (5:12)
Key findings from the Phase III HARMONi-2 study; ongoing Phase III HARMONi-7 study (9:59)
Clinician insights about the potential role of ivonescimab in the front-line setting (12:02)
Impetus for investigating ivonescimab in the relapsed/refractory (R/R) EGFR-mutant setting (14:01)
Key findings from the Phase III HARMONi-A and HARMONi studies (16:07)
Clinician insights about the potential role of ivonescimab in the treatment of R/R EGFR-mutant NSCLC; other novel PD-1/PD-L1 x VEGF bispecific antibodies under investigation (20:30)

CME information and select publications

Chronic Lymphocytic Leukemia — Microlearning Activity 2 Oct 16, 2026

Show notes

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00)
Role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy for relapsed/refractory (R/R) CLL (10:42)
Fixed-duration venetoclax in combination with epcoritamab for R/R CLL/SLL; management of Richter’s transformation (15:50)
Novel Bruton tyrosine kinase degraders bexobrutideg (NX-5948) and tacabrutideg (BGB-16673) (22:51)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Oncology Today with Dr Neil Love

Related Podcasts

Links

Stay Connected